Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udayan Chatterji

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of Virology|August 17, 2004
Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade CSohela de Rozières, Candace K Mathiason, Matthew R Rolston, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 28, 2007
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1Lot de Witte, Michael Bobardt, Udayan Chatterji, et al.
The Open Virology Journal|March 16, 2018
Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized MicePhilippe A Gallay, Udayan Chatterji, Aaron Kirchhoff, et al.
Journal of Virology|October 20, 2006
Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cellsMichael D Bobardt, Udayan Chatterji, Suganya Selvarajah, et al.
Plos One|February 5, 2019
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidateMichael Bobardt, Joseph Kuo, Udayan Chatterji, et al.
The Journal of Biological Chemistry|April 22, 2009
The isomerase active site of cyclophilin A is critical for hepatitis C virus replicationUdayan Chatterji, Michael Bobardt, Suganya Selvarajah, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus ChallengeRonald S Veazey, Udayan Chatterji, Michael Bobardt, et al.
Journal of Hepatology|August 21, 2012
HCV NS5A and IRF9 compete for CypA bindingMichael Bobardt, Sam Hopkins, James Baugh, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2019
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease ModelsJoseph Kuo, Michael Bobardt, Udayan Chatterji, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivirJose A Garcia-Rivera, Michael Bobardt, Udayan Chatterji, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Virology|August 17, 2004
Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade CSohela de Rozières, Candace K Mathiason, Matthew R Rolston, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 28, 2007
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1Lot de Witte, Michael Bobardt, Udayan Chatterji, et al.
The Open Virology Journal|March 16, 2018
Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized MicePhilippe A Gallay, Udayan Chatterji, Aaron Kirchhoff, et al.
Journal of Virology|October 20, 2006
Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cellsMichael D Bobardt, Udayan Chatterji, Suganya Selvarajah, et al.
Plos One|February 5, 2019
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidateMichael Bobardt, Joseph Kuo, Udayan Chatterji, et al.
The Journal of Biological Chemistry|April 22, 2009
The isomerase active site of cyclophilin A is critical for hepatitis C virus replicationUdayan Chatterji, Michael Bobardt, Suganya Selvarajah, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus ChallengeRonald S Veazey, Udayan Chatterji, Michael Bobardt, et al.
Journal of Hepatology|August 21, 2012
HCV NS5A and IRF9 compete for CypA bindingMichael Bobardt, Sam Hopkins, James Baugh, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2019
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease ModelsJoseph Kuo, Michael Bobardt, Udayan Chatterji, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivirJose A Garcia-Rivera, Michael Bobardt, Udayan Chatterji, et al.
Pageof 5